Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copaxone in girls with Rett syndrome
NCT02023424Phase 1Unknown
- Sponsor
- Sheba Medical Center
- Start
- Jan 2014
- Primary completion
- Sep 2014
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of glatiramer acetate in Rett syndrome (RTT), sponsored by Sheba Medical Center. Primary endpoints: Epileptiform activity at 26 weeks and Adverse Events at 26 weeks. Status: unknown.
02
Drugs
glatiramer acetate
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on NCT02023424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02023424.